Drug Profile


Alternative Names: TDZD-8

Latest Information Update: 29 Apr 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Rochester
  • Developer Panther Biotechnology; University of Rochester
  • Class Anti-ischaemics; Antineoplastics; Neuroprotectants; Small molecules; Thiazolidines
  • Mechanism of Action Apoptosis stimulants; Protein kinase inhibitors; Stem cell inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Leukaemia

Most Recent Events

  • 17 Apr 2015 Panther Biotechnology in-licenses the development and commercial rights for TDZD 8 from the University of Rochester
  • 17 Apr 2015 Panther Biotechnology has patents pending for TDZD 8 in USA and European Union
  • 17 Apr 2015 Preclinical trials in Leukaemia in USA (unspecified route) before April 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top